Abstract
One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Current Alzheimer Research
Title: A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP
Volume: 4 Issue: 4
Author(s): Michal Arbel and Beka Solomon
Affiliation:
Keywords: Alzheimer's disease, APP, Aβ, β-secretase site, BACE1, Endocytic pathway, Intracellular Aβ, Monoclonal antibodies
Abstract: One of the main neuropathological lesions observed at brain autopsy of Alzheimers disease (AD) patients are the extracellular senile plaques mainly composed of amyloid-β (Aβ) peptides. Aβ is generated by proteolytic processing of amyloid precursor protein (APP) via β and γ-secretases. The β-secretase APP cleaving enzyme 1 (BACE1) has become a target of intense research aimed at blocking the enzyme activity. Recent studies showed that BACE1 is involved in processing other non-APP substrates, and that other proteases are involved in APP processing. We have recently established a novel approach to inhibit Aβ production via antibodies against the β-secretase cleavage site of APP. These antibodies bind wild type and Swedish mutated APP expressed in transgenic mice brain tissues. The isolated antibodies do not bind any form of Aβ peptides. Antibody up-take experiments, using Chinese hamster ovary cells expressing wild-type APP, suggest that antibody internalization and trafficking are mediated via the endocytic pathway. Administration of antibodies to the cells growing media resulted in a considerable decrease in intracellular Aβ levels, as well as in the levels of the corresponding C-terminal fragment (C99). The relevance of intra-neuronal accumulation of mainly Aβ42 as an early event in AD pathogenesis suggests that this approach may be applicable as a novel therapeutic strategy in AD treatment.
Export Options
About this article
Cite this article as:
Arbel Michal and Solomon Beka, A Novel Immunotherapy for Alzheimers Disease: Antibodies against the β-Secretase Cleavage Site of APP, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788792
DOI https://dx.doi.org/10.2174/156720507781788792 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autophagy in the Central Nervous System: Implications for Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Editorial [Hot Topic: Amyloid-Associated Disease Mechanisms in Alzheimers Disease (Guest Editor: Jeroen J.M. Hoozemans)]
Current Drug Targets - CNS & Neurological Disorders Nanostructures for Drug Delivery to the Brain
Current Medicinal Chemistry Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Editorial [Hot Topic: Alzheimerss Disease, Dementia and Cognitive Decline (Executive Editors: J.E. Starrett, Jr. and G.S. Poindexter)]
Current Pharmaceutical Design On the Possible Relevance of Bottom-up Pathways in the Pathogenesis of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Screening Methods for Antioxidants-A Review
Mini-Reviews in Medicinal Chemistry Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening The Blood-Brain Barrier in NeuroAIDS
Current HIV Research 2-Arylbenzothiazole as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism Erratum
Current Alzheimer Research Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Phenylbutyric Acid Protects Against Spatial Memory Deficits in a Model of Repeated Electroconvulsive Therapy
Current Neurovascular Research Solution NMR Studies of Aβ Monomer Dynamics
Protein & Peptide Letters Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets